A study from Lund University in Sweden, published in the journal Nature Aging, has found that an improved blood test for Alzheimer's disease can now diagnose the condition with the same reliability as the more invasive cerebrospinal fluid (CSF) test that has long been the clinical standard.

According to Lund University, the blood test measures the protein p-tau217, a biomarker specific to Alzheimer's disease, and has already received regulatory approval for clinical use in Europe, the United States, and Japan. The researchers behind the study hope that the findings will encourage wider adoption of the blood test in healthcare settings, potentially sparing many patients the need for a lumbar puncture, which is required to obtain cerebrospinal fluid.

"These new findings are based on cutoff values that directly reflect clinical practice. The results show that this improved blood test, which has previously received FDA approval and CE marking for clinical use, is just as accurate as the established cerebrospinal fluid test – detecting Alzheimer's disease pathology with at least 90 percent accuracy. It is the first time this has been demonstrated," said Noëlle Warmenhoven, a doctoral student in the Clinical Memory Research Unit at Lund University and a co-author of the study.

The researchers used PET imaging to verify the accuracy of the blood test results. The study evaluated the test across three different cohorts: an American research cohort, a Swedish memory clinic cohort, and a Swedish primary care cohort. In all three groups, the blood test and the CSF test performed equally well.

A key design element of the study was the use of predefined, regulatory-approved cutoff values to determine whether a test result was positive, inconclusive, or negative. Previous research on blood tests for Alzheimer's has often relied on cutoff values calculated specifically for the study in question, which may not translate well to broader clinical populations. Warmenhoven explained that a cutoff that works perfectly in one study group could produce many false positives when applied to a different group with a different proportion of healthy individuals. The predefined cutoffs used in the current study are the same ones that physicians would use in practice.

"Previous studies have used cerebrospinal fluid tests as a reference standard. Based on those articles, there are many clinicians that therefore believe the new blood tests are good, but probably not as good as the cerebrospinal fluid tests we already use. However, the findings of this new study contradict this and suggest that a blood test is just as accurate as cerebrospinal fluid testing," said Sebastian Palmqvist, associate professor and senior lecturer in neurology at Lund University and senior consultant at the Memory Clinic, Skåne University Hospital.

The blood test is currently recommended only for use in memory clinics and other specialist healthcare settings, not in primary care. Palmqvist noted that work is underway to determine how the test might eventually be implemented in primary care. Further down the line, he added, it could also become relevant to screen people who have no memory problems at all, should drug treatments prove effective at that stage.

Alzheimer's disease affects one in five women and one in ten men over their lifetime, according to Lund University. While specialised memory clinics have access to advanced diagnostic tools such as PET scans and CSF tests, primary care has long lacked simple and quick diagnostic methods.

The blood test measures the protein p-tau217, a biomarker specific to Alzheimer's disease. A separate US-approved version of the test also measures the protein Aβ42 (amyloid-beta 42), which accumulates in the brain and forms plaques in people with Alzheimer's. However, the Lund researchers have previously shown – and confirmed again in this study – that the combined measurement does not necessarily outperform measuring p-tau217 alone.

The test can return a positive, negative, or inconclusive result. If the result is inconclusive, further investigation using a PET scan or CSF test may be required for a more reliable diagnosis. The patient must have cognitive symptoms for the test to be clinically relevant.

The study was funded by a range of organisations, including the National Institute on Aging, the European Research Council, the Alzheimer's Association, the Swedish Research Council, and several foundations. The researchers stated that none of the co-authors have any conflict of interest in relation to the test. The test is manufactured by Fujirebio and made available for clinical use in Sweden. The tests were purchased using external research funding and were not sponsored analyses. The researchers have not received any financial compensation from the company, and the company was not involved in the research.